{"id":70754,"date":"2026-05-12T10:43:33","date_gmt":"2026-05-12T10:43:33","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&#038;p=70754"},"modified":"2026-10-15T10:33:58","modified_gmt":"2026-10-15T10:33:58","slug":"mazdutide","status":"publish","type":"product","link":"https:\/\/medsbase.com\/pt-br\/product\/mazdutide\/","title":{"rendered":"Mazdutide"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">Resposta R\u00e1pida \u2014 O que \u00e9 Mazdutide?<\/h3>\n<p style=\"margin: 0;\"><strong>Mazdutide<\/strong> (developmental codes IBI362 \/ LY3305677) is a long-acting dual GLP-1 and glucagon receptor co-agonist peptide developed by Innovent Biologics (in-licensed from Eli Lilly). It is the first dual GLP-1\/glucagon agonist to reach Phase 3 trials in obesity and type 2 diabetes, with the glucagon component adding an energy-expenditure mechanism beyond what GLP-1-only and GLP-1\/GIP-dual peptides produce. Plasma half-life supports once-weekly dosing. Supplied in 5\u00a0mg and 10\u00a0mg lyophilized vials.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>O que voc\u00ea obt\u00e9m com a MedsBase:<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/pt-br\/reviews\/\">\ud83d\udce6 Cada pedido \u00e9 coberto pela nossa<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Todo pedido \u00e9 coberto pelo nosso <a href=\"https:\/\/medsbase.com\/pt-br\/medsbase-re-shipment-assurance-policy\/\"><strong>Pol\u00edtica de Reenvio Garantido<\/strong><\/a> \u2014 se sua encomenda n\u00e3o chegar em 20 dias \u00fateis, n\u00f3s a reenviamos.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Especifica\u00e7\u00e3o<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">Detalhe<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>N\u00famero CAS<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">2376247-09-1 (mazdutide; comumente citado)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Tipo<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Co-agonista dual de longa a\u00e7\u00e3o dos receptores GLP-1 \/ glucagon (pept\u00eddeo sint\u00e9tico acilado; Innovent IBI362 \/ Eli Lilly LY3305677; estrutura derivada de oxintomodulina)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Peso Molecular<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">~4.865 Da (com acila\u00e7\u00e3o de \u00e1cido graxo; forma madura publicada)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Estrutura<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Pept\u00eddeo sint\u00e9tico baseado na estrutura natural da oxintomodulina (o agonista dual end\u00f3geno GLP-1\/glucagon), com substitui\u00e7\u00f5es projetadas para resist\u00eancia \u00e0 DPP-4 e um ligante de \u00e1cido graxo acilado anexado a um res\u00edduo de lisina via um ligante \u03b3-Glu. A cadeia acilada promove a liga\u00e7\u00e3o revers\u00edvel \u00e0 albumina s\u00e9rica que produz a meia-vida semanal prolongada.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Forma<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">P\u00f3 liofilizado (branco a branco amarelado)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Pureza<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599% (verificado por HPLC, COA sob solicita\u00e7\u00e3o)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Armazenamento<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Liofilizado: 2\u20138 \u00b0C (geladeira) para estoque de trabalho; \u221220 \u00b0C para armazenamento de longo prazo de frascos fechados. Reconstitu\u00eddo: 2\u20138 \u00b0C, usar em at\u00e9 ~30 dias. Proteger da luz. N\u00e3o congelar e descongelar a solu\u00e7\u00e3o reconstitu\u00edda.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Solubilidade<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u00c1gua bacteriost\u00e1tica (recomendada) ou \u00e1gua est\u00e9ril para janelas de uso mais curtas. Pept\u00eddeos acilados podem dissolver mais lentamente \u2014 permita tempo extra de equil\u00edbrio.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>O que \u00e9 Mazdutide?<\/h2>\n<p><strong>Mazdutide<\/strong> is a long-acting synthetic dual GLP-1 and glucagon receptor co-agonist developed under the developmental codes IBI362 (Innovent Biologics, in-licensed from Eli Lilly LY3305677). It is one of the most advanced compounds in the renewed wave of oxyntomodulin-derived dual-agonist pharmacology \u2014 an approach distinct from both the GLP-1-only programme (semaglutide) and the GLP-1\/GIP dual-agonist programme (tirzepatide). The structural inspiration is oxyntomodulin itself, a 37-amino-acid product of preproglucagon processing in intestinal L-cells that natively activates both the GLP-1 and glucagon receptors. Endogenous oxyntomodulin has very short pharmacokinetics; mazdutide engineers around this with a fatty-acid acyl tether at a lysine residue that drives reversible serum-albumin binding and extends the plasma half-life sufficiently for once-weekly subcutaneous administration in clinical studies. Mazdutide has a mature molecular weight of approximately 4,865\u00a0Da including the acyl modification. The structural scaffold preserves the dual-receptor pharmacology of oxyntomodulin while engineered substitutions confer resistance to DPP-4-mediated proteolytic cleavage that would otherwise produce rapid clearance. Mazdutide is the lead Chinese metabolic peptide programme, with Phase 3 trials (GLORY-1 in obesity, DREAMS-1 and DREAMS-2 in type 2 diabetes) reporting body-weight reductions of approximately 15\u201317% at the highest dose tier over 48 weeks. Outside China, mazdutide is <strong>n\u00e3o aprovado<\/strong> by the FDA, EMA, MHRA, or any other major Western regulator. In China, mazdutide has been approved by the NMPA under its initial commercial brand \u2014 making it one of the first dual-agonist incretin peptides to receive regulatory clearance for human use anywhere. For the triple-agonist comparator that adds GIP on top of the same GLP-1\/glucagon combination, see our <a href=\"https:\/\/medsbase.com\/pt-br\/retatrutide\/\">Retatrutida<\/a> p\u00e1gina de produto. <\/p>\n<h2>Mecanismo de A\u00e7\u00e3o \u2014 Coagonismo Dual dos Receptores de GLP-1 \/ Glucagon<\/h2>\n<p>O que torna o mazdutide mecanicamente distinto entre os pept\u00eddeos metab\u00f3licos duplos-agonistas atuais \u00e9 que ele combina o eixo can\u00f4nico de saciedade\/glic\u00eamico do GLP-1 com o <strong>eixo de gasto energ\u00e9tico do receptor de glucagon<\/strong> \u2014 not the GIP receptor axis used by tirzepatide. The dual-receptor profile produces complementary effects across three principal compartments documented in published studies:<\/p>\n<ul>\n<li><strong>Ativa\u00e7\u00e3o do receptor GLP-1 \u2014 saciedade, secre\u00e7\u00e3o de insulina pelas c\u00e9lulas \u03b2, esvaziamento g\u00e1strico<\/strong> \u2014 O mazdutide ativa o receptor de GLP-1 nas c\u00e9lulas beta pancre\u00e1ticas (secre\u00e7\u00e3o de insulina dependente de glicose), nos neur\u00f4nios POMC do n\u00facleo arqueado hipotal\u00e2mico (sinaliza\u00e7\u00e3o central de saciedade) e nos aferentes vagais g\u00e1stricos (atraso no esvaziamento g\u00e1strico). Este bra\u00e7o se sobrep\u00f5e ao mecanismo do semaglutida e ao componente GLP-1 do tirzepatida e do retatrutida.<\/li>\n<li><strong>Ativa\u00e7\u00e3o do receptor de glucagon \u2014 gasto energ\u00e9tico, mobiliza\u00e7\u00e3o lip\u00eddica hep\u00e1tica, ativa\u00e7\u00e3o do tecido adiposo marrom<\/strong> \u2014 The defining feature of mazdutide is the simultaneous activation of the glucagon receptor. Glucagon-receptor agonism increases resting energy expenditure modestly, drives hepatic fatty-acid oxidation and lipid mobilisation from steatotic liver, and contributes to brown adipose tissue activation in published rodent studies. The energy-expenditure component is what distinguishes glucagon-containing multi-agonists (mazdutide, retatrutide, survodutide) from the body-weight effect of GLP-1-only and GLP-1\/GIP-dual peptides \u2014 the latter produce weight loss almost entirely through reduced energy intake, while glucagon-containing agonists add a metabolic-rate component.<\/li>\n<li><strong>Equil\u00edbrio de atividade receptora e o \u201cparadoxo do glucagon\u201d<\/strong> \u2014 O desafio farmacol\u00f3gico no coagonismo do receptor de glucagon \u00e9 alcan\u00e7ar um efeito l\u00edquido ben\u00e9fico: o glucagon sozinho eleva a glicose ao estimular a produ\u00e7\u00e3o hep\u00e1tica de glicose, o que pioraria em vez de melhorar o controle glic\u00eamico. O componente GLP-1 do mazdutide sobrep\u00f5e o efeito glic\u00eamico impulsionado pelo glucagon atrav\u00e9s da a\u00e7\u00e3o dominante de redu\u00e7\u00e3o da glicose na insulina e supress\u00e3o do glucagon nas c\u00e9lulas beta e alfa, enquanto o bra\u00e7o do glucagon preserva os benef\u00edcios de mobiliza\u00e7\u00e3o lip\u00eddica e gasto energ\u00e9tico. A pot\u00eancia relativa do receptor GLP-1 para glucagon \u00e9 projetada para favorecer o efeito l\u00edquido de redu\u00e7\u00e3o da glicose \u2014 uma diferen\u00e7a importante dos agonistas triplos como <a href=\"https:\/\/medsbase.com\/pt-br\/retatrutide\/\">retatrutide<\/a> onde o GIP tamb\u00e9m contribui.<\/li>\n<\/ul>\n<p>The fatty-acid acyl tether attached at a lysine residue binds reversibly to circulating serum albumin, producing a plasma depot that extends the effective half-life to support once-weekly subcutaneous dosing in clinical studies. Subcutaneous administration is the standard administration route. The mechanism for sustained-release distribution is analogous to semaglutide&#8217;s C18 and tirzepatide&#8217;s C20 fatty-acid systems but with different chain length and linker chemistry tuned to mazdutide&#8217;s dual-receptor pharmacology. <\/p>\n<h2>Published Evidence<\/h2>\n<p>Mazdutide is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>Obesity and body-composition studies<\/strong> \u2014 preclinical DIO rodent models, body-composition (DEXA\/MRI), food-intake assays, respiratory exchange ratio and resting energy expenditure; canonical dual GLP-1\/glucagon peptide<\/li>\n<li><strong>Type 2 diabetes preclinical studies<\/strong> \u2014 controle glic\u00eamico, substitutos de HbA1c, din\u00e2mica de supress\u00e3o de glucagon, sensibilidade \u00e0 insulina em modelos de dieta rica em gordura e roedores db\/db; compara\u00e7\u00e3o direta com agonistas \u00fanicos de GLP-1 e comparadores duais GLP-1\/GIP<\/li>\n<li><strong>MASLD\/MASH (doen\u00e7a hep\u00e1tica associada \u00e0 disfun\u00e7\u00e3o metab\u00f3lica)<\/strong> \u2014 conte\u00fado de triglicer\u00eddeos hep\u00e1ticos, ALT\/AST, estadiamento de fibrose; interesse particular devido \u00e0 atividade de mobiliza\u00e7\u00e3o lip\u00eddica do bra\u00e7o de glucagon em f\u00edgado esteat\u00f3tico<\/li>\n<li><strong>Energy-expenditure studies<\/strong> \u2014 medi\u00e7\u00e3o do gasto energ\u00e9tico em repouso, ativa\u00e7\u00e3o do tecido adiposo marrom, express\u00e3o g\u00eanica termog\u00eanica; dissec\u00e7\u00e3o mecanicista do componente da taxa metab\u00f3lica impulsionado pelo glucagon<\/li>\n<li><strong>Comparative dual-agonist studies<\/strong> \u2014 compara\u00e7\u00e3o direta com o agonista dual alternativo <a href=\"https:\/\/medsbase.com\/pt-br\/tirzepatide\/\">Tirzepatide<\/a> (GLP-1\/GIP) e o triplo-agonista <a href=\"https:\/\/medsbase.com\/pt-br\/retatrutide\/\">Retatrutida<\/a> (GLP-1\/GIP\/glucagon); receptor-stacking strategy studies<\/li>\n<li><strong>Cardiovascular and renal studies<\/strong> \u2014 efeitos sobre press\u00e3o arterial, perfis lip\u00eddicos, progress\u00e3o da aterosclerose em ApoE<sup>-\/-<\/sup> modelos; conjunto de dados emergentes dada a matura\u00e7\u00e3o do mazdutide na Fase 3<\/li>\n<li><strong>Farmacologia do eixo do glucagon<\/strong> \u2014 caracteriza\u00e7\u00e3o farmacol\u00f3gica isolada do receptor de glucagon, din\u00e2mica de produ\u00e7\u00e3o hep\u00e1tica de glicose, equil\u00edbrio entre supress\u00e3o de glucagon e agonismo de glucagon em mol\u00e9culas de agonistas duais<\/li>\n<li><strong>Comparative incretin studies<\/strong> \u2014 compara\u00e7\u00e3o com agonista \u00fanico de GLP-1 (<a href=\"https:\/\/medsbase.com\/pt-br\/semaglutide\/\">Semaglutide<\/a>), agonista dual GLP-1\/GIP (<a href=\"https:\/\/medsbase.com\/pt-br\/tirzepatide\/\">Tirzepatide<\/a>), e o triplo agonista GLP-1\/GIP\/glucagon (<a href=\"https:\/\/medsbase.com\/pt-br\/retatrutide\/\">Retatrutida<\/a>).<\/li>\n<\/ul>\n<p>Para um contexto mais amplo sobre onde o mazdutide se encaixa no cen\u00e1rio dos pept\u00eddeos metab\u00f3licos multi-agonistas, consulte <a href=\"https:\/\/medsbase.com\/pt-br\/retatrutide\/\">Retatrutida<\/a> como o comparador triplo-agonista que adiciona GIP, <a href=\"https:\/\/medsbase.com\/pt-br\/tirzepatide\/\">Tirzepatide<\/a> como a alternativa dual-agonista que utiliza GIP em vez de glucagon, <a href=\"https:\/\/medsbase.com\/pt-br\/semaglutide\/\">Semaglutide<\/a> como a linha de base de agonista \u00fanico, e <a href=\"https:\/\/medsbase.com\/pt-br\/cagrilintide\/\">Cagrilintide<\/a> como a alternativa de farmacologia combinada no eixo da amilina. Navegue pelo <a href=\"https:\/\/medsbase.com\/pt-br\/peptides\/\">cat\u00e1logo de pept\u00eddeos<\/a> para compostos relacionados. <\/p>\n<h2>Concentra\u00e7\u00f5es e Dosagens Dispon\u00edveis<\/h2>\n<p>MedsBase stocks Mazdutide in two lyophilized vial sizes calibrated to typical protocol lengths. Each strength is available in 10-vial, 20-vial, or 30-vial pack formats with full reconstitution guidance:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Dosagem do Frasco<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Caso de Uso T\u00edpico<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Tamanhos de Embalagem<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>5 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standard strength \u2014 pilot dosing, single-cohort protocols, titration arms<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>10 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Protocolos de ciclo estendido, estudos de m\u00faltiplas coortes, menor custo por mg<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Both strengths are the same chemical form (lyophilized powder, 99%+ HPLC purity). Phase 3 clinical doses are 4\u20139\u00a0mg weekly, so pharmaceutical-grade vials at 5\u00a0mg or 10\u00a0mg represent single-to-multi-week supplies of clinical-equivalent dosing for in-vivo work. Mazdutide is a comparatively scarce peptide because of structural complexity and active clinical development, which is reflected in the per-mg price relative to mature small synthetic peptides. <\/p>\n<h2>Como ele se compara \u2014 Mazdutide vs Retatrutide<\/h2>\n<p>Mazdutide e <a href=\"https:\/\/medsbase.com\/pt-br\/retatrutide\/\">Retatrutida<\/a> are the two canonical glucagon-receptor-containing multi-agonist metabolic peptides in current studies. They share the GLP-1 + glucagon backbone and differ in whether they also activate the GIP receptor \u2014 Retatrutide does (triple agonist), Mazdutide does not (dual agonist). The comparison is one of the cleanest in current metabolic-peptide pharmacology because the GLP-1 and glucagon arms are shared, isolating the contribution of the GIP component. <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Crit\u00e9rio<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Mazdutide<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Retatrutida<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Perfil de receptor<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GLP-1 + glucagon (dual)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GLP-1 + GIP + glucagon (triplo)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Estrutura<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Derivado de oxintomodulina<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Derivado de GIP<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Comprimento<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~39 amino\u00e1cidos<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">39 amino\u00e1cidos<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Meia-vida<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Semanal (acilado)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~6 dias<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Desenvolvedor \/ origem<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Innovent (IBI362) \/ Eli Lilly (LY3305677)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Eli Lilly (LY3437943)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Status regulat\u00f3rio<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Aprovado na China (NMPA); investigacional em outros lugares<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Investigacional (Fase 3)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Efeito sobre o peso corporal<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~15\u201317% (GLORY-1 Fase 3, 48 semanas)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~24% (Fase 2, 48 semanas)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Typical studies weekly dose<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">4\u20139\u00a0mg<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">2\u201312 mg<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The principal pharmacological question separating the two is the value of GIP receptor activation on top of GLP-1 + glucagon. Retatrutide&#8217;s Phase 2 body-weight effect is larger, suggesting GIP adds substantial benefit, but the more selective dual-agonist profile of mazdutide produces a potentially cleaner side-effect signal that may matter for long-term tolerability studies. For glucagon-axis-specific pharmacology, mazdutide is the cleaner tool because it isolates the GLP-1 + glucagon combination without the confound of GIP. For maximum-magnitude body-weight studies, the triple-agonist <a href=\"https:\/\/medsbase.com\/pt-br\/retatrutide\/\">retatrutide<\/a> permanece como a refer\u00eancia can\u00f4nica. <\/p>\n<h2>Armazenamento e Reconstitui\u00e7\u00e3o<\/h2>\n<p><strong>Antes da reconstitui\u00e7\u00e3o:<\/strong> armazene frascos liofilizados refrigerados a 2\u20138\u00a0\u00b0C na embalagem original para estoque de trabalho de curto prazo. Para armazenamento de longo prazo n\u00e3o aberto, congele a \u221220\u00a0\u00b0C. O Mazdutide liofilizado \u00e9 est\u00e1vel sob refrigera\u00e7\u00e3o por at\u00e9 24 meses e a \u221220\u00a0\u00b0C por at\u00e9 36 meses. Evite ciclos de congelamento e descongelamento no p\u00f3 liofilizado. <strong>Procedimento de reconstitui\u00e7\u00e3o:<\/strong> inject bacteriostatic water down the side wall of the vial (not directly onto the lyophilized cake). For a 5\u00a0mg vial, 2.0\u00a0mL of bacteriostatic water yields a 2.5\u00a0mg\/mL working concentration \u2014 0.04\u00a0mL delivers 100\u00a0mcg; 0.2\u00a0mL delivers 500\u00a0mcg; ~1.6\u00a0mL delivers a 4\u00a0mg clinical-equivalent dose. Swirl gently \u2014 do <strong>n\u00e3o<\/strong> sacuda \u2014 e permita 5\u201310 minutos para dissolu\u00e7\u00e3o completa (pept\u00eddeos acilados dissolvem-se mais lentamente do que pept\u00eddeos menores n\u00e3o modificados). Uma solu\u00e7\u00e3o corretamente reconstitu\u00edda deve estar clara e incolor, sem part\u00edculas vis\u00edveis. <strong>Ap\u00f3s a reconstitui\u00e7\u00e3o:<\/strong> armazene refrigerado a 2\u20138 \u00b0C e use dentro de 30 dias para estabilidade ideal. N\u00e3o congele a solu\u00e7\u00e3o reconstitu\u00edda \u2014 ciclos de congelamento-descongelamento degradam a integridade do pept\u00eddeo. Descarte qualquer frasco que apresente turva\u00e7\u00e3o, precipitado ou descolora\u00e7\u00e3o. <\/p>\n<h2 id=\"faqs\">Perguntas Frequentes<\/h2>\n<h3>What is Mazdutide used for in studies?<\/h3>\n<p>Mazdutide is used in studies investigating the dual GLP-1 \/ glucagon receptor co-agonist axis, obesity and body-composition regulation, type 2 diabetes preclinical models, MASLD\/MASH liver disease, energy-expenditure and thermogenesis, and comparative multi-agonist incretin pharmacology against single-agonist GLP-1, dual GLP-1\/GIP (tirzepatide), and triple GLP-1\/GIP\/glucagon (retatrutide) compounds. It is the most-cited Chinese-origin metabolic peptide in current literature. The pharmaceutical-grade mazdutide sold here is <strong>n\u00e3o<\/strong> FDA-approved and is supplied strictly for clinical studies use only. <\/p>\n<h3>Como o Mazdutide \u00e9 diferente do Semaglutida?<\/h3>\n<p>O Semaglutida \u00e9 um agonista \u00fanico do receptor GLP-1. O Mazdutide adiciona agonismo do receptor de glucagon al\u00e9m do GLP-1. O componente adicional de glucagon contribui com um mecanismo de gasto energ\u00e9tico \u2014 aumento da taxa metab\u00f3lica basal, mobiliza\u00e7\u00e3o lip\u00eddica hep\u00e1tica e ativa\u00e7\u00e3o do tecido adiposo marrom \u2014 que os agonistas apenas de GLP-1 n\u00e3o produzem. Em ensaios de fase 3 compar\u00e1veis, o Mazdutide produz um efeito de peso corporal um pouco maior do que o Semaglutida sozinho (15\u201317% vs ~15%), mas a principal diferen\u00e7a pr\u00e1tica \u00e9 a justificativa mec\u00e2nica para a perda de peso: o Semaglutida principalmente atrav\u00e9s da redu\u00e7\u00e3o da ingest\u00e3o de alimentos, o Mazdutide atrav\u00e9s da redu\u00e7\u00e3o da ingest\u00e3o e aumento do gasto energ\u00e9tico. <\/p>\n<h3>Como o Mazdutide \u00e9 diferente do Tirzepatida?<\/h3>\n<p>Both are dual incretin agonists, but they activate different second receptors. Tirzepatide is GLP-1 + GIP. Mazdutide is GLP-1 + glucagon. The two receptor combinations produce qualitatively different metabolic profiles: GIP (tirzepatide) adds adipocyte lipolysis under fasting conditions and modest effects on energy expenditure; glucagon (mazdutide) adds substantial energy expenditure and hepatic lipid mobilisation. Tirzepatide has the larger Phase 3 dataset and larger body-weight effect; mazdutide has the unique mechanism for MASLD\/MASH studies given the glucagon-driven hepatic lipid component. <\/p>\n<h3>Como o Mazdutide \u00e9 diferente do Retatrutida?<\/h3>\n<p>Retatrutide is a triple agonist (GLP-1 + GIP + glucagon). Mazdutide is a dual agonist that shares the GLP-1 + glucagon arms but lacks the GIP component. Retatrutide&#8217;s Phase 2 body-weight effect is larger than mazdutide&#8217;s Phase 3 result, suggesting GIP receptor activation adds substantial benefit on top of GLP-1 + glucagon. For studies isolating the GLP-1 + glucagon combination specifically, mazdutide is the cleaner tool because it avoids the GIP confound; for maximum body-weight effect, retatrutide remains the canonical reference. <\/p>\n<h3>What is the typical Mazdutide dose?<\/h3>\n<p>Published preclinical and clinical studies protocols use weekly subcutaneous dosing with a titration schedule starting at 1.5\u20133\u00a0mg and increasing to maintenance doses of 4\u20139\u00a0mg weekly \u2014 the dose range used in GLORY-1 and DREAMS-1 Phase 3 trials. A 5\u00a0mg vial reconstituted with 2.0\u00a0mL bacteriostatic water yields 2.5\u00a0mg\/mL \u2014 ~1.6\u00a0mL equals a 4\u00a0mg clinical-equivalent dose. <\/p>\n<h3>O Mazdutide \u00e9 aprovado pela FDA?<\/h3>\n<p>No. Mazdutide is not FDA-approved in the United States, nor is it EMA- or MHRA-approved. It has been approved by China&#8217;s NMPA for human use (one of the first dual GLP-1\/glucagon agonists to receive any regulatory approval worldwide), but Western regulatory submission is still pending or ongoing as of current literature. <\/p>\n<h3>Como o Mazdutide deve ser armazenado?<\/h3>\n<p>Frascos liofilizados: refrigerados a 2\u20138 \u00b0C para estoque de trabalho em curto prazo, ou \u221220 \u00b0C para armazenamento em longo prazo de frascos n\u00e3o abertos. Solu\u00e7\u00e3o reconstitu\u00edda: refrigerada a 2\u20138 \u00b0C, usar dentro de 30 dias. N\u00e3o congele a solu\u00e7\u00e3o reconstitu\u00edda \u2014 ciclos de congelamento e descongelamento degradam o pept\u00eddeo. Proteja da luz direta em todos os momentos. <\/p>\n<h3>Como devo reconstituir o Mazdutide?<\/h3>\n<p>Siga o procedimento de reconstitui\u00e7\u00e3o acima. Adicione \u00e1gua bacteriost\u00e1tica pela parede lateral do frasco (n\u00e3o diretamente sobre o p\u00f3 liofilizado), agite suavemente e aguarde 5\u201310 minutos para dissolu\u00e7\u00e3o completa (pept\u00eddeos acilados dissolvem-se mais lentamente do que pept\u00eddeos menores n\u00e3o modificados). N\u00e3o <strong>n\u00e3o<\/strong> Agite o frasco. Uma solu\u00e7\u00e3o corretamente reconstitu\u00edda \u00e9 clara e incolor. Para um frasco de 5 mg + 2,0 mL de diluente, a concentra\u00e7\u00e3o de trabalho \u00e9 de 2,5 mg\/mL. <\/p>\n<h3>Quais dosagens a MedsBase oferece?<\/h3>\n<p>MedsBase carries Mazdutide in 5\u00a0mg and 10\u00a0mg lyophilized vials. Each strength is available in 10-vial, 20-vial, or 30-vial pack sizes. All vials are supplied at 99%+ HPLC purity with a certificate of analysis available on request. <\/p>\n<h3>Por que o Mazdutide tamb\u00e9m ativa o receptor de glucagon?<\/h3>\n<p>A inspira\u00e7\u00e3o estrutural para o Mazdutide \u00e9 a oxintomodulina, um produto end\u00f3geno de 37 amino\u00e1cidos do processamento de pr\u00e9-proglucagon em c\u00e9lulas L intestinais que ativa naturalmente tanto os receptores de GLP-1 quanto de glucagon. A farmacologia dupla, portanto, n\u00e3o \u00e9 projetada \u2014 ela \u00e9 herdada do arcabou\u00e7o natural da oxintomodulina. O que \u00e9 projetado \u00e9 a resist\u00eancia \u00e0 clivagem pela DPP-4 e a acila\u00e7\u00e3o de \u00e1cido graxo que produz meia-vida semanal, juntamente com o ajuste fino da pot\u00eancia relativa do receptor de GLP-1 versus glucagon para favorecer o efeito l\u00edquido de redu\u00e7\u00e3o da glicose. <\/p>\n<h3>O componente glucagon causa hiperglicemia?<\/h3>\n<p>This is the classic &#8220;glucagon paradox&#8221; in dual-agonist studies. Glucagon alone raises glucose by stimulating hepatic glucose output, which would worsen rather than improve diabetes. In mazdutide, the GLP-1 component overrides this through dominant glucose-lowering action on insulin and glucagon-suppression at beta- and alpha-cells, while the glucagon arm preserves the lipid-mobilisation and energy-expenditure benefits. Published studies confirms net glucose-lowering despite glucagon receptor activation, demonstrating that the engineered GLP-1-to-glucagon potency ratio achieves the desired balance. <\/p>\n<h3>Does Mazdutide cause side reported effects?<\/h3>\n<p>O achado mais consistente \u00e9 gastrointestinal, semelhante a outros pept\u00eddeos do eixo GLP-1 \u2014 n\u00e1usea, supress\u00e3o transit\u00f3ria do apetite e esvaziamento g\u00e1strico retardado s\u00e3o dose-dependentes e tendem a atenuar ap\u00f3s 4\u20138 semanas de dosagem cont\u00ednua, conforme ocorre taquifilaxia do receptor. Achados relacionados ao componente do glucagon incluem eleva\u00e7\u00f5es modestas na frequ\u00eancia card\u00edaca em repouso e (raramente) efeitos transit\u00f3rios na press\u00e3o arterial. Dados de seguran\u00e7a em longo prazo continuam a ser acumulados a partir dos ensaios de Fase 3 na China e da vigil\u00e2ncia p\u00f3s-aprova\u00e7\u00e3o. <\/p>\n<h3>Qual \u00e9 a meia-vida do Mazdutide?<\/h3>\n<p>Mazdutide has a plasma half-life sufficient to support once-weekly subcutaneous dosing in clinical studies, achieved through reversible binding to serum albumin via the fatty-acid acyl tether. The exact half-life is somewhat shorter than semaglutide (~165 hours) but in the same once-weekly dosing regime. The dosing schedule and clinical trial design treat it as a fully once-weekly compound. <\/p>\n<h3>How long does Mazdutide take to show effects in preclinical studies?<\/h3>\n<p>Efeitos farmacodin\u00e2micos agudos na toler\u00e2ncia \u00e0 glicose e no esvaziamento g\u00e1strico s\u00e3o detect\u00e1veis dentro de horas ap\u00f3s a primeira dose. Efeitos no peso corporal em modelos de roedores com obesidade induzida por dieta (DIO) geralmente se tornam estatisticamente significativos ap\u00f3s 1\u20132 semanas de dosagem semanal e continuam a acumular-se ao longo de 8\u201316 semanas. O efeito m\u00e1ximo na composi\u00e7\u00e3o corporal se desenvolve ao longo de 16\u201324 semanas de dosagem cont\u00ednua, refletindo a trajet\u00f3ria da Fase 3 humana no estudo GLORY-1. <\/p>\n<h3>Posso encomendar Mazdutide para envio internacional?<\/h3>\n<p>Sim. A MedsBase envia Mazdutide para todo o mundo a partir de nossa rede dedicada de envio de pept\u00eddeos. Pedidos exclusivos de pept\u00eddeos se qualificam para nosso servi\u00e7o de envio de pept\u00eddeos independente. Todos os pedidos s\u00e3o enviados em embalagens com controle de temperatura, com rastreamento completo e cobertos por nossa <a href=\"https:\/\/medsbase.com\/pt-br\/medsbase-re-shipment-assurance-policy\/\">Pol\u00edtica de Reenvio Garantido<\/a>. <!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Peptides for Metabolic, Body-Composition, and Multi-Agonist Studies<\/h2>\n<ul>\n<li><a href=\"\/pt-br\/retatrutide\/\"><strong>Retatrutida<\/strong><\/a> \u2014 Agonista triplo de GLP-1\/GIP\/glucagon \u2014 adiciona GIP ao perfil de receptor do Mazdutide<\/li>\n<li><a href=\"\/pt-br\/tirzepatide\/\"><strong>Tirzepatide<\/strong><\/a> \u2014 Agonista duplo de GLP-1\/GIP \u2014 alternativa de agonista duplo utilizando GIP em vez de glucagon<\/li>\n<li><a href=\"\/pt-br\/semaglutide\/\"><strong>Semaglutide<\/strong><\/a> \u2014 Agonista \u00fanico de GLP-1 \u2014 comparador de linha de base can\u00f4nico<\/li>\n<li><a href=\"\/pt-br\/cagrilintide\/\"><strong>Cagrilintide<\/strong><\/a> \u2014 An\u00e1logo de amilina \u2014 abordagem alternativa de farmacologia combinada (CagriSema)<\/li>\n<li><a href=\"\/pt-br\/tesamorelin\/\"><strong>Tesamorelina<\/strong><\/a> \u2014 GHRH analog \u2014 visceral adiposity<\/li>\n<\/ul>\n<p><!-- medsbase-peptide-guide-cta --><\/p>\n<h2>Leitura Adicional<\/h2>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<p style=\"margin: 0 0 8px 0;\"><strong>\ud83d\udcd6 Explore o cen\u00e1rio de pept\u00eddeos metab\u00f3licos multi-agonistas<\/strong><\/p>\n<p style=\"margin: 0;\">Navegue pela categoria completa <a href=\"https:\/\/medsbase.com\/pt-br\/peptides\/\"><strong>cat\u00e1logo de pept\u00eddeos<\/strong><\/a>, com compostos relacionados incluindo <a href=\"https:\/\/medsbase.com\/pt-br\/retatrutide\/\">Retatrutida<\/a> (triplo-agonista), <a href=\"https:\/\/medsbase.com\/pt-br\/tirzepatide\/\">Tirzepatide<\/a> (dual GLP-1\/GIP), e <a href=\"https:\/\/medsbase.com\/pt-br\/semaglutide\/\">Semaglutide<\/a> (agonista \u00fanico). Guia comparativo: <a href=\"https:\/\/medsbase.com\/pt-br\/retatrutide-vs-tirzepatide\/\">Retatrutida vs Tirzepatida \u2014 agonista triplo vs dual<\/a>.<\/p>\n<\/div>\n<p><!-- pep-seo-v1 --><\/p>","protected":false},"excerpt":{"rendered":"<p>\u2705 Coagonista dual de receptor GLP-1 + glucagon<br \/>\n\u2705 Estrutura derivada de oxintomodulina (IBI362 \/ LY3305677)<br \/>\n\u2705 Adiciona mecanismo de gasto energ\u00e9tico al\u00e9m do GLP-1 isolado<br \/>\n\u2705 Aprovado na China; em investiga\u00e7\u00e3o no Ocidente<br \/>\n\u2705 Dosagem semanal<\/p>\n<p><strong>Mazdutide<\/strong> cont\u00e9m composto de pept\u00eddeo sint\u00e9tico.<\/p>","protected":false},"featured_media":70965,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[6285,5441],"class_list":["post-70754","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-mazdutide","product_tag-peptide","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/product\/70754","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/comments?post=70754"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/media\/70965"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/media?parent=70754"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/product_brand?post=70754"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/product_cat?post=70754"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/product_tag?post=70754"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}